Centiva Capital LP Makes New $307,000 Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Centiva Capital LP acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 10,727 shares of the specialty pharmaceutical company's stock, valued at approximately $307,000.

Other large investors have also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at about $40,000. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical in the fourth quarter worth approximately $230,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on COLL shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday. Finally, StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.80.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock worth $2,334,994 in the last ninety days. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $29.56 on Tuesday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The firm has a market cap of $949.82 million, a price-to-earnings ratio of 12.74 and a beta of 0.63. The business's fifty day moving average is $28.12 and its 200 day moving average is $29.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.